Connecting via Winsock to STN

Welcome to STN International! Enter x:x

FILE 'REGISTRY' ENTERED AT 16:34:53 ON 20 JUL 2010

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JUL 2010 HIGHEST RN 1233120-12-1
DICTIONARY FILE UPDATES: 19 JUL 2010 HIGHEST RN 1233120-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s trospium/cn
L1   1 TROSPIUM/CN

=> d l1

L1   ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN   47608-32-2 REGISTRY
ED   Entered STN: 16 Nov 1984
CN   Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
     3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
     3-[(hydroxydiphenylacetyl)oxy]-, (1α,3α,5α)- (9CI)
OTHER NAMES:
CN   Trospium
CN   Trospium cation
FS   STEREOSEARCH
DR   1001382-35-9, 1008557-44-5, 50857-35-7, 112726-87-1
MF   C25 H30 N O3
CI   COM
LC   STN Files: ADISNEWS, BEILSTEIN*, BIOSIS, CA, CAPLUS, CIN, DDFU, DRUGU,
       IMSPATENTS, IMSRESEARCH, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

96 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
96 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> fil caplus biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       8.58       8.80

FILE 'CAPLUS' ENTERED AT 16:36:19 ON 20 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:36:19 ON 20 JUL 2010
Copyright (c) 2010 The Thomson Corporation

=> d hist

     (FILE 'HOME' ENTERED AT 16:34:37 ON 20 JUL 2010)

     FILE 'REGISTRY' ENTERED AT 16:34:53 ON 20 JUL 2010
L1            1 S TROSPIUM/CN

     FILE 'CAPLUS, BIOSIS' ENTERED AT 16:36:19 ON 20 JUL 2010

=> s l1<chem>

   SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.47      10.27

FILE 'REGISTRY' ENTERED AT 16:37:08 ON 20 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

COPYRIGHT (C) 2010 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1- CHEM
L2 SEL L1 1- CHEM : 7 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.49	25.76

FILE 'CAPLUS' ENTERED AT 16:37:09 ON 20 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:37:09 ON 20 JUL 2010
Copyright (c) 2010 The Thomson Corporation

S L2
L3 410 L2

=> s l1 or l1<chem>

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.95	45.71

FILE 'REGISTRY' ENTERED AT 16:37:42 ON 20 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1- CHEM
L4 SEL L1 1- CHEM : 7 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.49	61.20

FILE 'CAPLUS' ENTERED AT 16:37:43 ON 20 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:37:43 ON 20 JUL 2010
Copyright (c) 2010 The Thomson Corporation

S L1 OR L4

L6 410 L1 OR L5

=> s l1 or trospium
L7 410 L1 OR TROSPIUM

=> s chronic(w)obstructive(w)pulmonary(w)disease
L8 30471 CHRONIC(W) OBSTRUCTIVE(W) PULMONARY(W) DISEASE

=> s copd
L9 16648 COPD

=> s l8 or l9
L10 31693 L8 OR L9

=> s l6 and l10
L11 13 L6 AND L10

=> dup remove l11
PROCESSING COMPLETED FOR L11
L12 13 DUP REMOVE L11 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-13

L12 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:116017 CAPLUS Full-text
DOCUMENT NUMBER: 152:177190
TITLE: Complex of trospium and pharmaceutical compositions thereof
INVENTOR(S): Scher, David S.; Ryznal, Rachel A.; Blizzard, Charles D.
PATENT ASSIGNEE(S): Alkermes, Inc., USA
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010011813	A1	20100128	WO 2009-US51498	20090723

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2008-83104P P 20080723
AB The invention is directed to a complex of trospium and saccharin. In one embodiment, the complex is a crystalline form. In another embodiment, the complex is a monohydrate form. The invention also encompasses methods of preparing the saccharin complex of trospium and to pharmaceutical compns. thereof. Thus, solution containing trospium chloride and water was combined with a solution containing sodium saccharin in water; the solns. were combined at a 1:1 mol. ratio of trospium chloride:sodium saccharin (2:1 mass ratio); upon mixing at room temperature, precipitate was visible in less than a minute; over several minutes, the amount of solids in the suspension increased; the solids were confirmed to be crystals by microscopy; trospium saccharin complex is soluble in water at room temperature at less than about 0.4 mg/mL.
IT 47608-32-2D, Trospium, complex with saccharin, monohydrate
RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(complex of trospium with saccharin and pharmaceutical compns. thereof)
RN 47608-32-2 CAPLUS
CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:273485 CAPLUS Full-text
DOCUMENT NUMBER: 152:304114
TITLE: Method and system using an anticholinergic agent and a high-efficiency nebulizer for the treatment of chronic obstructive pulmonary disease
INVENTOR(S): Gerhart, William; Tutuncu, Ahmet
PATENT ASSIGNEE(S): Elevation Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S. Ser. No. 393,709.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20100055045	A1	20100304	US 2009-547406		20090825
US 20090215734	A1	20090827	US 2009-393709		20090226
PRIORITY APPLN. INFO.:			US 2008-31639P	P	20080226
			US 2008-80184P	P	20080711
			US 2009-393709	A2	20090226

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A method is provided for improving lung function in COPD by administering a muscarinic antagonist, e.g. glycopyrrolate, with a high efficiency nebulizer.

IT 47608-32-2, Trospium 47608-32-2D, Trospium, derivs., salts, enantiomers, or diastereomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(muscarinic antagonist and high-efficiency nebulizer for treatment of chronic obstructive pulmonary disease)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:974352 CAPLUS Full-text
DOCUMENT NUMBER: 149:252424
TITLE: Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the beta 2 adrenergic receptor
INVENTOR(S): Puig Duran, Carlos; Moyes Valls, Enrique
PATENT ASSIGNEE(S): Laboratorios Almirall S.A., Spain
SOURCE: PCT Int. Appl., 32pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008095720	A1	20080814	WO 2008-EP975	20080208
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2306595	A1	20081101	ES 2007-362	20070209
ES 2306595	B1	20090911		
AU 2008213109	A1	20080814	AU 2008-213109	20080208
CA 2677610	A1	20080814	CA 2008-2677610	20080208
KR 2009111321	A	20091026	KR 2009-716590	20080208
EP 2121615	A1	20091125	EP 2008-707620	20080208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
JP 2010518038	T	20100527	JP 2009-548626	20080208
ZA 2009004851	A	20100428	ZA 2009-4851	20090710
IN 2009DN04675	A	20100514	IN 2009-DN4675	20090717
CN 101679269	A	20100324	CN 2008-80004323	20090806
MX 2009008462	A	20090916	MX 2009-8462	20090807
US 20100093681	A1	20100415	US 2009-526090	20091008

PRIORITY APPLN. INFO.: ES 2007-362 A 20070209
WO 2008-EP975 W 20080208
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI



I

AB The present invention is directed to cryst. mononapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2- phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one (I) and pharmaceutically acceptable solvates thereof. Naphthalene-1,5-disulfonic acid tetrahydrate is added to a heated solution of I in methanol to give I heminapadisylate salt. Inhalation pharmaceutical formulations are given containing I napadisylate salt.

IT 47608-32-2D, Trospium, salt
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one napadisylate as β-2 adrenoceptor agonist)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:529495 CAPLUS Full-text
DOCUMENT NUMBER: 148:509924
TITLE: New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit; Himmelsbach, Frank; Pohl, Gerald
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co.Kg
SOURCE: PCT Int. Appl., 96pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008049842	A2	20080502	WO 2007-EP61355	20071023
WO 2008049842	A3	20080918		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2667543	A1	20080502	CA 2007-2667543	20071023
EP 2086641	A2	20090812	EP 2007-821719	20071023
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2010507617	T	20100311	JP 2009-533814	20071023
US 20100099651	A1	20100422	US 2009-446794	20090618
PRIORITY APPLN. INFO.:			US 2006-862990P P	20061026
			WO 2007-EP61355 W	20071023

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to novel pharmaceutical compns. comprising at least one EGFR kinase inhibitor and at least one addnl. active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, anticholinergics and endothelin antagonists, processes for preparing the compns. and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

IT 47608-32-2D, Trospium, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new pharmaceutical compns. for treatment of respiratory and gastrointestinal disorders)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:97712 CAPLUS Full-text

DOCUMENT NUMBER: 150:229080

TITLE: Research progress in the muscarinic receptor antagonists

AUTHOR(S): Li, Ning; Kang, Congmin; Lu, Yingtao
CORPORATE SOURCE: College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, Peop. Rep. China
SOURCE: Huaxue Tongbao (2008), 71(12), 923-929
CODEN: HHTPAU; ISSN: 0441-3776
PUBLISHER: Huaxue Tongbao Bianjibu
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Chinese

AB A review. Muscarinic receptor is one of the most important cholinergic receptor in human organisms. It distributes extensively in human central and peripheral nerve systems, myocardium, smooth muscle and glandular organs and involves in various physiol. function. Therefore, designing and synthesizing compds. that can inhibit or stimulate muscarinic receptor become a significant way of researching drugs for diseases such as Over Active Bladder, Chronic Obstructive Pulmonary Disease, Myopia and Arrhythmia. The progress in study on antagonists of various muscarinic subtypes is introduced in brief.

L12 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1361773 CAPLUS Full-text
DOCUMENT NUMBER: 148:17680
TITLE: Hydroxy-substituted phenethylamine derivative combinations with anticholinergic agents and steroids for the treatment of respiratory diseases and other conditions
INVENTOR(S): Konetzki, Ingo
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 66pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007134964	A1	20071129	WO 2007-EP54487	20070509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2653105	A1	20071129	CA 2007-2653105	20070509
EP 2029126	A1	20090304	EP 2007-728939	20070509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009537585	T	20091029	JP 2009-511446	20070509

PRIORITY APPLN. INFO.:		
EP 2006-114541	A	20060524
EP 2006-115462	A	20060614
WO 2007-EP54487	W	20070509

OTHER SOURCE(S): MARPAT 148:17680
GI



I

AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula (I; wherein A = phenylene or -C1-5-alkylene; B = single bond phenylene, -C1-5-alkylene or -C1-3-alkylene-O-C1-3-alkylene, optionally substituted by OH or -O-C1-4-alkyl; X = -NH- or -O-; R1 = -CH2-OH, or -NH-CHO; R2 = H, or R1 and R2 together = -NH-CO-CH=CH-; R3 = Ph, optionally substituted by -C1-4-alkyl, halogen, -O-C1-4-alkyl, -O-C1-4-alkylene-NH2, -SO2NH2, -NH-CO-NH2, -SO2-C1-5-alkyl and -SO2-C3-6-cycloalkyl), at least one anticholinergic and at least one steroid, processes for preparing them and their use as pharmaceutical compns.

IT 47608-32-2D, Trospium, salts
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicament combinations comprising anticholinergics and steroids for treatment of respiratory diseases)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:438421 CAPLUS Full-text
DOCUMENT NUMBER: 146:448430
TITLE: Novel pharmaceutical combinations containing oxazine derivatives and tiotropium and related compounds for the treatment of respiratory disorders
INVENTOR(S): Bouyssou, Thierry; Pieper, Michael P.; Schnapp, Andreas
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 32pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007042467	A1	20070419	WO 2006-EP67122	20061006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070086957	A1	20070419	US 2006-543694	20061005
AU 2006301329	A1	20070419	AU 2006-301329	20061006
CA 2624584	A1	20070419	CA 2006-2624584	20061006
EP 1940409	A1	20080709	EP 2006-807024	20061006
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009511541	T	20090319	JP 2008-535000	20061006
ZA 2008001667	A	20090325	ZA 2008-1667	20080220
MX 2008004348	A	20080416	MX 2008-4348	20080401
CN 101282729	A	20081008	CN 2006-80037735	20080410
KR 2008067643	A	20080721	KR 2008-711117	20080508

PRIORITY APPLN. INFO.:			EP 2005-109374	A 20051010
			WO 2006-EP67122	W 20061006

OTHER SOURCE(S): MARPAT 146:448430
GI



I

AB The present invention relates to novel pharmaceutical combinations which, besides one or more, preferably one, compound of the general formula (I) in which the radicals R1, R2, and R3 have the meanings stated in the claims and in the description, comprise at least one further active ingredient , method for the manufacture thereof, and the use thereof as pharmaceutical. The drugs can be formulated sep. or together; tablets, inhalants are prepared No formulation example is given.

IT 47608-32-2D, Trospium, salts
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical combinations containing oxazine derivs. and tiotropium and related compds. for treatment of respiratory disorders)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA

INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:202111 CAPLUS Full-text
DOCUMENT NUMBER: 146:259006
TITLE: Trospium-containing compositions
INVENTOR(S): Ehrich, Elliot; Deaver, Daniel; Clarke, Robert; Lipp, Michael M.
PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 392,333.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070041912	A1	20070222	US 2005-550471	20050922
US 20040042970	A1	20040304	US 2003-392333	20030319
US 7754242	B2	20100713		
CA 2517265	A1	20041104	CA 2003-2517265	20030904
WO 2004093861	A1	20041104	WO 2003-US27618	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003273273	A1	20041119	AU 2003-273273	20030904
AU 2003273273	B2	20070208		
EP 1603547	A1	20051214	EP 2003-755776	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514679	T	20060511	JP 2004-571157	20030904
NZ 541745	A	20091127	NZ 2003-541745	20030904
IN 2005DN03513	A	20070817	IN 2005-DN3513	20050808

MX 2005009629	A	20051018	MX 2005-9629	20050908
AU 2006220411	A1	20061012	AU 2006-220411	20060920
AU 2006220411	B2	20080626		

PRIORITY APPLN. INFO.:

US 2003-392333	A2	20030319
WO 2003-US27618	W	20030904
US 2002-366354P	P	20020320
US 2002-366440P	P	20020320
US 2002-366449P	P	20020320
US 2002-366470P	P	20020320
US 2002-366479P	P	20020320
US 2002-366487P	P	20020320
AU 2003-230689	A3	20030319

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium , wherein said patient achieves an effective therapy for at least 10 h. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.

IT 47608-32-2, Trospium
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(trospium-containing compns.)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L12 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1339527 CAPLUS Full-text

DOCUMENT NUMBER: 146:87582

TITLE: MRP4 inhibitors for the treatment of respiratory diseases

INVENTOR(S): Goeggel, Rolf; Cui, Yunhai

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG

SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006134022	A1	20061221	WO 2006-EP62690	20060530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2611907	A1	20061221	CA 2006-2611907	20060530
EP 1898894	A1	20080319	EP 2006-763346	20060530
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008543806	T	20081204	JP 2008-516268	20060530
US 20060286041	A1	20061221	US 2006-424596	20060616

PRIORITY APPLN. INFO.: EP 2005-105363 A 20050617
WO 2006-EP62690 W 20060530

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 146:87582

AB The present invention relates to the use of MRP4 inhibitors for the treatment of respiratory diseases, pharmaceutical compns. containing them and processes for the preparation thereof.

IT 47608-32-2D, Trospium, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholinergic; MRP4 inhibitors in combination with other therapeutic agents for treatment of respiratory diseases)

RN 47608-32-2 CAPLUS
CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:606246 CAPLUS Full-text
DOCUMENT NUMBER: 145:55950
TITLE: Compositions and methods using muscarinic receptor antagonists and local anesthetics for pulmonary conditions
INVENTOR(S): Deaver, Daniel
PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065722	A2	20060622	WO 2005-US44858	20051213
WO 2006065722	A3	20060824		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005316687	A1	20060622	AU 2005-316687	20051213
AU 2005316687	B2	20080626		
CA 2588042	A1	20060622	CA 2005-2588042	20051213
US 20060134008	A1	20060622	US 2005-302526	20051213
EP 1824466	A2	20070829	EP 2005-853707	20051213
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008514648	T	20080508	JP 2007-533797	20051213

PRIORITY APPLN. INFO.:
US 2004-636755P P 20041216
WO 2005-US44858 W 20051213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Compns. and methods for the treatment of pulmonary conditions, esp. pulmonary conditions characterized by persistent cough, are disclosed. The compns. and methods employ at least one muscarinic receptor antagonist and at least one local anesthetic administered pulmonarily either simultaneously or in sequence. The compns. may be in powder or liquid form.

IT 47608-32-2, Trospium
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(muscarinic receptor antagonist- local anesthetic combination for treatment of pulmonary condition)

RN 47608-32-2 CAPLUS
CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1256669 CAPLUS Full-text
DOCUMENT NUMBER: 146:20293
TITLE: Novel medicament combinations for the treatment of respiratory diseases
INVENTOR(S): Pieper, Michael P.; Schnapp, Andreas; Nickolaus, Peter
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 33pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060270667	A1	20061130	US 2006-420872	20060530
CA 2609429	A1	20061207	CA 2006-2609429	20060529
WO 2006128847	A2	20061207	WO 2006-EP62683	20060529
WO 2006128847	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1893203	A2	20080305	EP 2006-763340	20060529
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008542332	T	20081127	JP 2008-514079	20060529

PRIORITY APPLN. INFO.: EP 2005-104702 A 20050531
WO 2006-EP62683 W 20060529
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 146:20293

AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, betamimetic, at least one anticholinergic and at least one PDE-IV inhibitor processes for preparing them and their use as pharmaceutical compns.

IT 47608-32-2D, Trospium, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel medicament combinations for treatment of respiratory diseases)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1155523 CAPLUS Full-text

DOCUMENT NUMBER: 143:416252

TITLE: Novel medicament combinations for the treatment of respiratory diseases

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: U.S. Pat. Appl. Publ., 50 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050239778	A1	20051027	US 2005-109094	20050419
DE 102004019540	A1	20051110	DE 2004-102004019540	20040422
DE 102004052987	A1	20060504	DE 2004-102004052987	20041103
AU 2005235419	A1	20051103	AU 2005-235419	20050418
CA 2559699	A1	20051103	CA 2005-2559699	20050418
WO 2005102349	A1	20051103	WO 2005-EP4073	20050418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1781298	A1	20070509	EP 2005-739576	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101035540	A	20070912	CN 2005-80012621	20050418
BR 2005010080	A	20071016	BR 2005-10080	20050418
JP 2007533683	T	20071122	JP 2007-508805	20050418
SG 152237	A1	20090529	SG 2009-2525	20050418
ZA 2006006624	A	20080130	ZA 2006-6624	20060808
MX 2006011721	A	20061211	MX 2006-11721	20061010
NO 2006005060	A	20061121	NO 2006-5060	20061102
KR 2007015592	A	20070205	KR 2006-724528	20061122
PRIORITY APPLN. INFO.:			DE 2004-102004019540A	20040422
			US 2004-578542P P	20040610
			DE 2004-102004052987A	20041103
			EP 2005-2496 A	20050207
			WO 2005-EP4073 W	20050418

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:416252
GI



I

AB The present invention relates to a pharmaceutical compn. comprising one or more compds. of formula I wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, and at least one other active substance for the treatment of respiratory diseases. The second active substance can by an anticholinergic, a phosphodiesterase IV inhibitor, a steroid, a LTD4 antagonist or an EGFR inhibitor.

IT 47608-32-2D, Trospium, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholinergics; novel medicament combinations for treatment of respiratory diseases)

RN 47608-32-2 CAPLUS

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1α,3α,5α)- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L12 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:504647 CAPLUS Full-text
DOCUMENT NUMBER: 137:83636
TITLE: Combination drugs containing NK-1 receptor antagonists and NK-2 receptor antagonists and/or cholinolytics
INVENTOR(S): Doi, Takayuki; Hashimoto, Tadatoshi; Kamo, Izumi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051440	A1	20020704	WO 2001-JP11231	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432543	A1	20020704	CA 2001-2432543	20011221
AU 2002217467	A1	20020708	AU 2002-217467	20011221
JP 2002249432	A	20020906	JP 2001-390486	20011221
EP 1352659	A1	20031015	EP 2001-271853	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040058914	A1	20040325	US 2003-451431	20030623

PRIORITY APPLN. INFO.: JP 2000-391013 A 20001222
WO 2001-JP11231 W 20011221
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:83636
GI



I

AB Disclosed are drugs useful as preventives and remedies for urinary frequency, urinary incontinence, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, arthritis deformans, pain, cough, irritable bowel syndrome, vomiting, depression, anxiety, manic-depression or schizophrenia which comprise a combination of an NK-1 receptor antagonist and an NK-2 receptor antagonist and/or a cholinolytic. More specifically, drugs comprising a combination of a compound represented by the following formula I [wherein the ring M represents a heterocycle having, as the partial structure -X-Y< thereof, -N=C<, -CO-N< or -CS-N<; Ra and Rb are bonded to each other to form the ring A, or Ra and Rb may be the same or different and each represents hydrogen or a substituent in the ring M; the rings A and B are each an optionally substituted homocycle or heterocycle and at least one of them is an optionally substituted heterocycle; the ring C is an optionally substituted homocycle or heterocycle; the ring Z is an optionally substituted nitrogen-containing heterocycle; and n is an integer of 1 to 6], its salt or a prodrug thereof with an NK-2 receptor antagonist and/or a cholinolytic. The effect of (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5- (4-methylphenyl)-6,13-dioxo-13H-[1,4]diazocino[2,1-g][1,7] naphthyridine and (±)SR48968 (saredutant) hydrochloride in cyclophosphamide-induced urinary frequency rats were examined OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(12 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:42:56 ON 20 JUL 2010